CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • CMPS Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Reddit
  • Community Notes
  • 6-K Filing

Compass Pathways (CMPS) 6-KCOMPASS Pathways granted fifth US patent for crystalline psilocybin

Filed: 23 Nov 21, 4:43pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 COMPASS Pathways granted fifth US patent for crystalline psilocybin
    CMPS similar filings
    • 22 Dec 21 COMPASS Pathways announces changes in Executive Team
    • 7 Dec 21 Current report (foreign)
    • 2 Dec 21 Current report (foreign)
    • 23 Nov 21 COMPASS Pathways granted fifth US patent for crystalline psilocybin
    • 9 Nov 21 Current report (foreign)
    • 9 Nov 21 COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial
    • 4 Nov 21 COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy
    Filing view
    Share this filing

       
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Form 6-K
    REPORT OF FOREIGN PRIVATE ISSUER
    Pursuant to Rule 13a-16 or 15d-16
    under the Securities Exchange Act of 1934
    For the month of November 2021
    Commission File Number: 001-39522

    COMPASS PATHWAYS PLC
    (Translation of registrant’s name into English)
    3rd Floor
    1 Ashley Road
    Altrincham
    Cheshire WA14 2DT
    United Kingdom
    Tel: +1 (646) 905-3974
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F ☒ Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐





    INFORMATION CONTAINED IN THIS FORM 6-K REPORT

    On November 23, 2021, COMPASS Pathways Plc (the “Company”) issued a press release titled “COMPASS Pathways granted fifth US patent for crystalline psilocybin.” A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    The information in this report included as Exhibit 99.1 and incorporated herein by reference shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to this report.

    image_1a.jpg
    EXHIBITS
    ExhibitDescription
    99.1
    Press Release dated November 23, 2021
    image_1a.jpg




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    COMPASS PATHWAYS PLC
    Date: November 23, 2021By:/s/ Piers Morgan
    Piers Morgan
    Chief Financial Officer



    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn